MAPT and frontotemporal dementia: Can regional MRI volumetry and FDG-PET hypometabolism differentiate underlying neuropathology, specifically discriminating between tau- and TDP-43-based FTD, hence facilitating appropriate patient stratification in clinical trials and pathology-targeted therapeutic intervention?